Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
In Phase 3 studies: Participants without diabetes taking orforglipron lost approximately 9% to 10% of body weight over roughly 36 to 40 weeks Participants with type 2 diabetes generally lost around 7% to 8% By comparison, Wegovy's landmark STEP trials reported approximately 14.9% average weight loss over 68 weeks
Schleifer, MD, President & CEO
Ali, A., Yaln, R
Samtidigt fr mer n 85 procent av personer med diabetes godknd behandling, och allmnlkare r bekvma med att frskriva dessa lkemedel
GLP-1 Receptor Agonists Genotype Report: Access this content: An active subscription is required to access this content
You can also see if you qualify for Noom Med
US$ 26.07
US$ 24.94
US$ 21.93
US$ 28.25
US$ 29.84
US$ 25.96
US$ 27.92
US$ 27.46
US$ 28.26
US$ 25.11
US$ 21.02
